FBRX
Income statement / Annual
Last year (2023), Forte Biosciences, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Forte Biosciences, Inc.'s net income was -$31.48 M.
See Forte Biosciences, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$18.04 M
|
$41,000.00
|
$49,000.00
|
$51,000.00
|
| Cost of Revenue |
$9,000.00 |
$0.00 |
$36,000.00 |
$54,000.00 |
$11,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$9,000.00 |
$0.00 |
-$36,000.00 |
-$54,000.00 |
-$11,000.00 |
$18.04 M |
$41,000.00 |
$49,000.00 |
$51,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$21.86 M
|
$5.59 M
|
$13.85 M
|
$10.00 M
|
$2.68 M
|
$50.46 M
|
$29.11 M
|
$27.22 M
|
$19.17 M
|
| General & Administrative
Expenses |
$10.62 M
|
$8.30 M
|
$7.63 M
|
$4.22 M
|
$1.38 M
|
$265,680.00
|
$8.56 M
|
$4.52 M
|
$3.83 M
|
| Selling & Marketing
Expenses |
-$9,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$12.54 M
|
-$292,000.00
|
-$255,000.00
|
-$232,000.00
|
| Selling, General &
Administrative Expenses |
$10.62 M
|
$8.30 M
|
$7.63 M
|
$4.22 M
|
$1.38 M
|
$12.81 M
|
$8.27 M
|
$4.27 M
|
$3.60 M
|
| Other Expenses |
-$1.00 |
$17,000.00 |
-$222,000.00 |
-$205,000.00 |
-$6,853.00 |
$0.00 |
$0.00 |
-$50,000.00 |
$0.00 |
| Operating Expenses |
$32.48 M |
$13.90 M |
$21.49 M |
$14.23 M |
$4.06 M |
$63.26 M |
$37.38 M |
$31.49 M |
$22.77 M |
| Cost And Expenses |
$32.49 M |
$13.90 M |
$21.49 M |
$14.23 M |
$4.06 M |
$63.89 M |
$37.67 M |
$31.74 M |
$23.01 M |
| Interest Income |
$1.12 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$595,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$173,380.00 |
$1.93 M |
-$1.84 M |
-$102,000.00 |
| Depreciation &
Amortization |
$9,000.00
|
$36,000.00
|
$36,000.00
|
$54,000.00
|
$11,000.00
|
$625,000.00
|
$292,000.00
|
$255,000.00
|
$232,000.00
|
| EBITDA |
-$32.48 M
|
-$13.90 M
|
-$21.45 M
|
-$46.43 M
|
-$4.05 M
|
-$43.69 M
|
-$36.71 M
|
-$31.17 M
|
-$22.49 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
-2.51 |
-910.66 |
-641.55 |
-445.53 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
-2.54
|
-917.78
|
-646.76
|
-450.08
|
| Total Other
Income/Expenses Net |
$1.01 M
|
$17,000.00
|
-$222,000.00
|
-$205,000.00
|
-$5,000.00
|
-$1.40 M
|
-$1.30 M
|
-$1.79 M
|
-$102,000.00
|
| Income Before Tax |
-$31.48 M |
-$13.88 M |
-$21.71 M |
-$46.49 M |
-$4.07 M |
-$47.26 M |
-$38.93 M |
-$33.48 M |
-$23.06 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
-2.62
|
-949.49
|
-683.22
|
-452.08
|
| Income Tax Expense |
$0.00 |
-$17,000.00 |
-$200,558.00 |
$32.06 M |
-$2,520.00 |
$1.70 M |
-$2.60 M |
-$3.67 M |
-$204,000.00 |
| Net Income |
-$31.48 M |
-$13.86 M |
-$21.71 M |
-$78.54 M |
-$4.07 M |
-$48.96 M |
-$38.93 M |
-$33.48 M |
-$23.06 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
-2.71 |
-949.49 |
-683.22 |
-452.08 |
| EPS |
-24.92 |
-19.96 |
-38.8535 |
-157.9272 |
-48.2512 |
-915.18 |
-997.5 |
-634.7962 |
-474.15 |
| EPS Diluted |
-24.92 |
-19.96 |
-38.8535 |
-157.9272 |
-48.2512 |
-915.18 |
-997.5 |
-634.7962 |
-474.15 |
| Weighted Average Shares
Out |
$1.26 M
|
$695,341.00
|
$558,712.00
|
$294,357.00
|
$84,330.00
|
$53,492.00
|
$38,953.00
|
$52,738.00
|
$48,626.00
|
| Weighted Average Shares
Out Diluted |
$1.26 M
|
$695,341.00
|
$558,712.00
|
$294,357.00
|
$84,330.00
|
$53,492.00
|
$38,953.00
|
$52,738.00
|
$48,626.00
|
| Link |
|
|
|
|
|
|
|
|
|
